Catalyst
Monitor the trial's primary and secondary outcomes, particularly the reduction in serum toxin levels and quality of life metrics over the 12-month period.
Date
June 29, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.